Reliq Health Technologies, Inc. Announces 15 New Skilled Nursing Facility Clients in California – Yahoo Finance
HAMILTON, Ontario, Nov. 17, 2022 (GLOBE NEWSWIRE) — Reliq Health Technologies Inc. (TSXV:RHT or OTC:RQHTF or WKN:A2AJTB) (“Reliq” or the “Company”), a rapidly growing global healthcare technology company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare market, today announced that it has signed a contract with a network of 15 Skilled Nursing Facilities (SNFs) in California. This contract is expected to add a further 1,000 new patients per month or 12,000 new patients per year to Reliq’s iUGO Care platform beginning in 2023.
“We are very pleased to be expanding into the Skilled Nursing Facility market in California,” said Dr. Lisa Crossley, CEO at Reliq Health Technologies, Inc. “Reliq will be providing our iUGO Care Transitional Care Management (TCM), Remote Patient Monitoring (RPM), Chronic Care Management (CCM) and Behavioural Health Integration (BHI) solutions to help improve post-discharge health outcomes and reduce readmissions, while also generating new revenue streams for the facilities. The Company will provide TCM to newly discharged patients at a rate of $60 per patient, with recurring revenue from RPM, CCM and BHI of $65/patient per month, at 75% gross margin. We will begin onboarding patients with these facilities in early 2023. Once all 15 facilities are live we expect to onboard over 1,000 of their newly discharged patients every month. The Skilled Nursing space is currently one of our fastest growing market segments and we are excited to help SNFs provide new healthcare services to their patients to drive better outcomes.”
Reliq Health
Reliq Health Technologies is a rapidly growing global healthcare technology company that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market. Reliq’s powerful iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits. Reliq Health Technologies trades on the TSX Venture under the symbol RHT, on the OTC as RQHTF and on the Frankfurt Stock Exchange under the WKN: A2AJTB.
ON BEHALF OF THE BOARD
“Dr. Lisa Crossley”
CEO and Director
For further information please contact:
Company Contact
Investor Relations at ir@reliqhealth.com
US Investor Relations Contact
Investor Relations
Lytham Partners, LLC
Ben Shamsian
New York | Phoenix
646-829-9701
shamsian@lythampartners.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statements Regarding Forward Looking Information
Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”.
We caution you that such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.
Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including technology development, anticipated revenues, projected size of market, and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.
Reliq Health Technologies Inc. (the “Company“) does not intend and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, technology development and marketing activities, the Company’s historical experience with technology development, uninsured risks. Actual results may differ materially from those expressed or implied by such forward-looking statements.
SOURCE: Reliq Health Technologies Inc.
Related Quotes
Trading resumes in:
2022 has undoubtedly been a rough one for investors. Even accounting for the recent gains, all the major indexes are still down for the year and the backdrop of economic uncertainty still hovers menacingly. Such an environment makes it difficult to find the stocks which are primed to charge ahead, but one way to sort the wheat from the chaff is to follow in the footsteps of legendary stock pickers. And few are as well-versed in the investing game as billionaire Steve Cohen. Famous for his high-r
From a $1 billion loan to Sam Bankman-Fried to missing funds and payment-disbursement emojis, here are some of the eye-popping revelations from FTX’s new CEO
What happened Next-generation fintech and digital bank Nu Holdings (NYSE: NU) had a lousy Thursday on the stock market. Somewhat counter-intuitively, given the company's recent financial performance, an analyst lowered his price target on the stock.
Shares of Editas Medicine (NASDAQ: EDIT) were down as much as 21% at one point on Thursday. Editas has a 52-week low of $9.59 and a 52-week high of $37.50, and is down more than 60% so far this year. The clinical-stage biotech, which seeks therapies through CRISPR gene-editing, paused its Brilliance Phase 1/2 trial for its lead therapy, EDIT-101, to treat the rare eye disease, leber congential amaurosis (LCA) 10, that affects the retina.
There were no expense controls for employees whose expenses were approved by chat with personalized emojis, according to the new CEO.
The Oracle of Omaha knows how to beat inflation. So ride his coattails.
Analysts are becoming increasingly wary about Nio's prospects, but they still see a strong upside in the EV stock.
Sam Bankman-Fried fires off a missive about financial regulators on Twitter and discusses them with a reporter.
Yahoo Finance Live checks out Alibaba shares following its Singles' Day sales and latest earnings report.
Investors know that the key to profits is in the return – and that means, a willingness to shoulder risk. Risk is relative, of course, and tends to run hand-in-hand with the return potential. Find a stock with a giant return potential, and chances are, you’ve also found one with a higher risk profile. The highest returns usually come along with the lowest share prices. After all, when a stock is priced for just pennies, even a small gain in share price translates into a huge return. Which means
Michael Burry is a savvy investor. He is one of the legends of Wall Street, which makes him one of those financiers whose every word is followed closely by millions of investors. Investors watch his strategies and the business choices he makes.
"I'm only happy when it rains," sang alternative rock band Garbage in the 1990s, and it's fair to say that Cathie Wood feels the same way. The co-founder, CEO, and chief stock picker of Ark Invest is a growth stock investor, but she also seems to be making opportunistic purchases when her holdings go the wrong way. Ark Invest only added to a couple of its position on Wednesday.
“They’re supposed to be the one guy at the party that doesn’t hang around the punch bowl getting drunk,” Munger said.
Yahoo Finance Live co-host Seana Smith examines several stocks trending in the after-hours trading session.
Shares of Twist Bioscience (NASDAQ: TWST) were crashing this week, plunging 37.2% as of the market close on Thursday, according to data provided by S&P Global Market Intelligence. The steep decline came after Scorpion Capital announced on Tuesday that it was short-selling the stock and released a scathing online report about the synthetic DNA maker. Scorpion accused Twist Bioscience of being "a cash-burning inferno that is not a going concern."
On Wednesday, Vox published a bombshell interview with former crypto exchange FTX CEO Sam Bankman-Fried, where the 30-year-old crypto trader all but revealed he had, in fact, co-mingled customer funds with those of his hedge fund, Alameda Research. This would be a problem on its own, as it violated FTX’s terms-of-service as well as likely falls afoul of wires or securities laws. Bankman-Fried’s crime, which “wasn’t quite lending [customer deposits] out” but something “messier,” “more organic” and “reasonable” than that, was compounded after a run on his exchange left up to one million FTX users without access to their funds.
Treasury I bonds weren't a good deal in October. They were a great deal with a 9.62% interest rate. Now it's time to consider buying the new I bond.
John Linehan, who manages $29 billion for T. Rowe Price, is looking to financials, energy and utilities to power the market as interest rates remain high.
Nvidia Corp.'s financial results had a bit of a surprise for investors, and not on the good side — product inventories doubled to a record high as the chip company gears up for a potentially iffy holiday season.